Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring

Emek Kocaturk, Sarbjit S. Saini, Christine J. Rubeiz, Jonathan A. Bernstein

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment of chronic spontaneous urticaria (CSU) is responsive to H1 antihistamines administered up to four times the recommended US Food and Drug Administration dose in approximately 50% of patients. However, when patients do not respond to these first-line agents, evidence-based guidelines using Grading of Recommendations, Assessment, Development, and Evaluations methodology have provided direction for second- and third-line treatments that can effectively treat patients with CSU. Some patients remain refractory to these advanced treatments; therefore, alternative treatments with a lower certainty of evidence may be necessary. Regardless of the therapies used to treat CSU patients, it is essential for clinicians to be knowledgeable about the mechanism of action, efficacy, and safety and monitoring recommendations of the treatments prescribed. This review provides a comprehensive review of the adverse effects and monitoring recommendations for agents in use for CSU treatment as well as those currently undergoing investigation for CSU treatment.

Original languageEnglish (US)
Pages (from-to)3099-3116
Number of pages18
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume10
Issue number12
DOIs
StatePublished - Dec 2022
Externally publishedYes

Keywords

  • Adverse effects
  • Alternative treatments
  • Anti-inflammatory medications
  • Biologics
  • Chronic spontaneous urticaria
  • H1 antihistamines
  • Immunosuppressants
  • Monitoring
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring'. Together they form a unique fingerprint.

Cite this